VA
PMVP icon

Verdad Advisers’s PMV Pharmaceuticals PMVP Stock Holding History

Verdad Advisers’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486K Buy
362,361
+182,200
+101% +$234K 0.47% 79
2026
Q1 		$223K Buy
+180,161
New +$229K 0.25% 125

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Verdad Advisers's PMVP Position: Q2 2026 in Review

Verdad Advisers increased its PMV Pharmaceuticals (PMVP) stake by 101% in Q2 2026, buying an estimated $234K and bringing the position to 362,361 shares worth $486K. The position accounts for 0.47% of the portfolio, ranked #79.

Verdad Advisers first reported a position in PMVP in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Verdad Advisers held 362,361 shares of PMV Pharmaceuticals worth $486K as of Q2 2026.
  • Verdad Advisers bought 182,200 PMV Pharmaceuticals shares in Q2 2026, an estimated $234K.
  • PMV Pharmaceuticals made up 0.47% of Verdad Advisers's portfolio in Q2 2026, its #79 holding.
  • Verdad Advisers first reported a position in PMV Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.